NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Matisse Pharmaceuticals

Matisse Pharmaceuticals

Private
GeleenHealthcare & Life Scienceshttps://www.matissepharmaceuticals.com/

Last Round

Grant

Jun 26, 2025

Total Funding Raised

$610,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Matisse Pharmaceuticals is a biopharmaceutical company developing a treatment for sepsis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Application

Keywords

sepsis therapyisupartob sodiumextracellular histoneshistone neutralizationseptic shock treatmentclinical-stage biopharmacompanion diagnosticCDxheparin-derived therapeuticcritical care medicinein vitro diagnosticIVDdrug developmentFDA Fast Trackmachine learning diagnosticpatient stratification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Matisse Pharmaceuticals Comparables

Compare Matisse Pharmaceuticals with similar companies based on industry and business-model similarity.

Matisse Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Inotrem
86%
Adrenomed AG
83%
RevImmune
81%

Matisse Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 26, 2025
VC RoundJan 4, 2024
VC RoundMar 1, 2020
SeedNov 15, 2016

Key People

Founding team and executive leadership

Kees Groen

Chief Executive Officer

Executive Team

Matisse Pharmaceuticals Investors

Notable investors and investment history

Matisse Pharmaceuticals investors
InvestorRounds
Mibiton FoundationSeed
Eurostars SME programmeGrant
Brightlands Venture PartnersVC Round, Seed
LIOFVC Round, Seed
Particon B.V.Seed
Netherlands Enterprise AgencyVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 176% MoM.

  • Feb 21, 2026

    Grew 67% QoQ, from 6 to 10 employees.

Matisse Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Matisse Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Matisse Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersGeleen
Employee Range10
Year Founded2014
Last FundingJun 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.